感染症診断の世界市場予測(~2022年):製品・サービス、疾患種類、技術、エンドユーザー

◆英語タイトル:Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022
◆商品コード:MAM-MD-3088
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2018年4月16日
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

MarketsandMarketsが発行した当調査レポートでは、感染症診断の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品・サービス別分析、疾患種類別分析、技術別分析、エンドユーザー別分析、感染症診断の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

“The global infectious disease diagnostics market is projected to grow at a CAGR of 5.6%.”The global infectious disease diagnostics market is expected to reach USD 19.35 billion by 2022 from USD 14.73 billion in 2017, at a CAGR of 5.6%. Growth in this market can primarily be attributed to factors such as increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics. However, inadequate reimbursement and rising healthcare cost limiting usage of novel diagnostic technologies are expected to restrain the growth of this market during the forecast period.
“The assays, kits, & reagents segment accounted for the largest share in 2017.”
Based on product & service, the infectious disease diagnostics market is segmented into assays, kits, & reagents; instruments; and services & software. The assays, kits, and reagents segment accounted for the largest share of the global infectious disease diagnostics market in 2017. The large share of this segment can be attributed to the increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages.
“Asia Pacific is projected to grow at the highest CAGR during the forecast period.”
Geographically, Asia Pacific is expected to register the highest CAGR during the forecast period. The growth of this regional segment can be attributed to the growing GDPs and a significant rise in disposable income levels, increased healthcare spending by a larger population base, modernization of healthcare infrastructure, and rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas).
Break-up profile of primaries:
• By Company Type- Tier 40%, Tier 30%, and Tier 30%
• By Designation-C-level-27%, D-level-18%, and Others-55%
• By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMerieux (France), Bio-Rad (US), and Roche (Switzerland).
Research Coverage:
The infectious disease diagnostics market in this report is segmented by product & service, disease type, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisitions, collaborations, agreements, partnerships, and expansions, and profiles key players and core competencies in the infectious disease diagnostics market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global infectious disease diagnostics market. The report analyzes the market by product & service, disease type, technology, end user, and region
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global infectious disease diagnostics market
Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for infectious disease diagnostic products across regions
Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global infectious disease diagnostics market
Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global infectious disease diagnostics market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 16
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
1.4 LIMITATIONS 17
1.5 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 PRIMARY DATA 19
2.1.1 KEY DATA FROM PRIMARY SOURCES 19
2.1.2 KEY INDUSTRY INSIGHTS 20
2.2 SECONDARY DATA 21
2.2.1 KEY DATA FROM SECONDARY SOURCES 21
2.3 MARKET SIZE ESTIMATION 22
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4.1 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 INFECTIOUS DISEASE DIAGNOSTICS: MARKET OVERVIEW 30
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY AND REGION (2017) 31
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017 VS. 2022 (USD BILLION) 32
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 32
5 MARKET OVERVIEW 33
5.1 INTRODUCTION 33
5.2 MARKET DYNAMICS 33
5.2.1 DRIVERS 34
5.2.1.1 Increasing global prevalence of infectious diseases 34
5.2.1.2 Shift in focus from centralized laboratories to decentralized point-of-care testing 34
5.2.1.3 Growth in funding for research on infectious disease diagnostics 35
5.2.2 RESTRAINTS 35
5.2.2.1 Inadequate reimbursements 35
5.2.2.2 Rising healthcare costs limiting the use of novel diagnostic techniques 36
5.2.3 OPPORTUNITIES 36
5.2.3.1 Advances in genomics and proteomics 36
5.2.3.2 Growing awareness about personalized medicine 37
5.2.3.3 Growth opportunities in emerging markets 37
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 38
6.1 INTRODUCTION 39
6.2 ASSAYS, KITS, & REAGENTS 40
6.3 INSTRUMENTS 41
6.4 SERVICES & SOFTWARE 42
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 44
7.1 INTRODUCTION 45
7.1.1 IMMUNODIAGNOSTICS 46
7.1.2 CLINICAL MICROBIOLOGY 47
7.1.3 POLYMERASE CHAIN REACTION (PCR) 49
7.1.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 50
7.1.5 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 51
7.1.6 DNA MICROARRAY 52
7.1.7 OTHER TECHNOLOGIES 53
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE 55
8.1 INTRODUCTION 56
8.1.1 HEPATITIS 57
8.1.1.1 Hepatitis diagnostics market, by technology 58
8.1.2 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 59
8.1.3 CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA (CT/NG) 60
8.1.4 HOSPITAL-ACQUIRED INFECTIONS (HAIS) 61
8.1.5 HUMAN PAPILLOMAVIRUS (HPV) 62
8.1.6 TUBERCULOSIS (TB) 63
8.1.6.1 Tuberculosis diagnostics market, by technology 64
8.1.7 INFLUENZA 65
8.1.7.1 Influenza diagnostics market, by technology 66
8.1.8 OTHER INFECTIOUS DISEASES 66
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 68
9.1 INTRODUCTION 69
9.2 HOSPITAL/CLINICAL LABORATORIES 70
9.3 REFERENCE LABORATORIES 71
9.4 PHYSICIAN OFFICES 72
9.5 ACADEMIC/RESEARCH INSTITUTES 73
9.6 OTHER END USERS 74
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 76
10.1 INTRODUCTION 77
10.2 NORTH AMERICA 78
10.2.1 US 82
10.2.2 CANADA 85
10.3 EUROPE 88
10.4 ASIA PACIFIC (APAC) 91
10.5 REST OF THE WORLD (ROW) 95
11 COMPETITIVE LANDSCAPE 98
11.1 MARKET OVERVIEW 98
11.2 MARKET RANKING ANALYSIS, 2017 99
11.3 COMPETITIVE SITUATION AND TRENDS 100
11.3.1 PRODUCT LAUNCHES AND APPROVALS 100
11.3.2 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS 101
11.3.3 ACQUISITIONS 102
11.3.4 EXPANSIONS 103
12 COMPANY PROFILES 104
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ABBOTT LABORATORIES 104
12.2 BECTON, DICKINSON AND COMPANY 108
12.3 BIOMÉRIEUX SA 112
12.4 BIO-RAD LABORATORIES 118
12.5 DANAHER CORPORATION 123
12.6 DIASORIN 130
12.7 LUMINEX 136
12.8 MERIDIAN BIOSCIENCE 139
12.9 QUIDEL 143
12.10 ROCHE DIAGNOSTICS 148
12.11 SIEMENS AG 152
12.12 THERMO FISHER SCIENTIFIC 156

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13 APPENDIX 161
13.1 DISCUSSION GUIDE 161
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 164
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 166
13.4 AVAILABLE CUSTOMIZATIONS 168
13.5 RELATED REPORTS 169
13.6 AUTHOR DETAILS 170

LIST OF TABLES

TABLE 1 NEW TESTS LAUNCHED BY KEY PLAYERS 36
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 39
TABLE 3 INFECTIOUS DISEASE DIAGNOSTIC ASSAYS, KITS, & REAGENTS MARKET,
BY REGION, 2015–2022 (USD MILLION) 40
TABLE 4 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC ASSAYS, KITS, & REAGENTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 40
TABLE 5 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION,
2015–2022 (USD MILLION) 41
TABLE 6 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 42
TABLE 7 INFECTIOUS DISEASE DIAGNOSTIC SERVICES & SOFTWARE MARKET,
BY REGION, 2015–2022 (USD MILLION) 43
TABLE 8 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 9 INFECTIOUS DISEASES DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 46
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS,
BY REGION, 2015–2022 (USD MILLION) 47
TABLE 11 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION) 47
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY,
BY REGION, 2015–2022 (USD MILLION) 48
TABLE 13 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2015–2022 (USD MILLION) 48
TABLE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION,
2015–2022 (USD MILLION) 49
TABLE 15 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR,
BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION,
2015–2022 (USD MILLION) 50
TABLE 17 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 18 DNA SEQUENCING & NGS MARKET, BY REGION, 2015–2022 (USD MILLION) 51
TABLE 19 NORTH AMERICA: DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 52
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY,
BY REGION, 2015–2022 (USD MILLION) 52
TABLE 21 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY COUNTRY, 2015–2022 (USD MILLION) 53
TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2015–2022 (USD MILLION) 54
TABLE 23 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION) 54
TABLE 24 INFECTIOUS DISEASES DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 57
TABLE 25 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 58
TABLE 26 NORTH AMERICA: HEPATITIS DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 58
TABLE 27 HEPATITIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 58
TABLE 28 HIV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 59
TABLE 29 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 60
TABLE 30 CT/NG DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 60
TABLE 31 NORTH AMERICA: CT/NG DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 61
TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 62
TABLE 33 NORTH AMERICA: HAI DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 62
TABLE 34 HPV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 63
TABLE 35 NORTH AMERICA: HPV DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 63
TABLE 36 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 64
TABLE 37 NORTH AMERICA: TUBERCULOSIS DIAGNOSTICS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 64
TABLE 38 TUBERCULOSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 64
TABLE 39 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 65
TABLE 40 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 65
TABLE 41 INFLUENZA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 66
TABLE 42 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2015–2022 (USD MILLION) 67
TABLE 43 NORTH AMERICA: OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 67
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2015–2022 (USD MILLION) 69
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL/CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION) 70
TABLE 46 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL/CLINICAL LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION) 71
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY REGION, 2015–2022 (USD MILLION) 71
TABLE 48 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION) 72
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES,
BY REGION, 2015–2022 (USD MILLION) 72
TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2015–2022 (USD MILLION) 73
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC/RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION) 73
TABLE 52 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC/RESEARCH INSTITUTES, BY COUNTRY, 2015–2022 (USD MILLION) 74
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY REGION, 2015–2022 (USD MILLION) 74
TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET
FOR OTHER END USERS, BY COUNTRY, 2015–2022 (USD MILLION) 75

TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2015–2022 (USD MILLION) 78
TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 80
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 80
TABLE 58 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2015–2022 (USD MILLION) 81
TABLE 59 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2015–2022 (USD MILLION) 81
TABLE 60 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2015–2022 (USD MILLION) 82
TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 83
TABLE 62 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 83
TABLE 63 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 84
TABLE 64 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 84
TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 85
TABLE 66 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 86
TABLE 67 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 86
TABLE 68 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 87
TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 88
TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 89
TABLE 72 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 89
TABLE 73 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 90
TABLE 75 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 93
TABLE 76 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 93
TABLE 77 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 94
TABLE 78 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 94
TABLE 80 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 95
TABLE 81 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 96
TABLE 82 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2015–2022 (USD MILLION) 96

TABLE 83 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 97
TABLE 84 RANK OF COMPANIES IN THE GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, 2017 99
TABLE 85 PRODUCT LAUNCHES, 2015-2018 100
TABLE 86 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2015 & 2018 101
TABLE 87 ACQUISITIONS, 2015-2017 102
TABLE 88 EXPANSIONS, 2015 TO 2017 103


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 18
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 21
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 23
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 23
FIGURE 5 DATA TRIANGULATION 24
FIGURE 6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017 VS. 2022 26
FIGURE 7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017 VS. 2022 27
FIGURE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017 VS. 2022 27
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 28
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 29
FIGURE 11 INCREASING PREVALENCE OF INFECTIOUS DISEASES IS A KEY DRIVER FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 30
FIGURE 12 IMMUNODIAGNOSTICS TECHNOLOGY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2017 31
FIGURE 13 ASSAYS, KITS & REAGENTS WILL CONTINUE TO DOMINATE THE INFECTIOUS DISEASE DIAGNOSTICS MARKET IN 2022 32
FIGURE 14 HOSPITALS & CLINICAL LABORATORIES ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2017 32
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 33
FIGURE 16 ASSAYS, KITS, & REAGENTS TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 39
FIGURE 17 IMMUNODIAGNOSTICS TO DOMINATE THE IDD MARKET DURING THE FORECAST PERIOD (2017–2022) 45
FIGURE 18 HEPATITIS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE THE IDD MARKET DURING THE FORECAST PERIOD (2017–2022) 56
FIGURE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2022 (USD MILLION) 69
FIGURE 20 GEOGRAPHICAL SNAPSHOT: ASIA PACIFIC TO BE THE FASTEST-GROWING REGIONAL SEGMENT IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 77
FIGURE 21 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 79
FIGURE 22 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 92
FIGURE 23 KEY DEVELOPMENTS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET BETWEEN 2013 AND 2016 98
FIGURE 24 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016) 104
FIGURE 25 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017) 108
FIGURE 26 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2016) 112
FIGURE 27 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2016) 118
FIGURE 28 DANAHER CORPORATION: COMPANY SNAPSHOT (2016) 123
FIGURE 29 DIASORIN: COMPANY SNAPSHOT (2017) 130
FIGURE 30 LUMINEX: COMPANY SNAPSHOT (2016) 136

FIGURE 31 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017) 139
FIGURE 32 QUIDEL: COMPANY SNAPSHOT (2016) 143
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017) 148
FIGURE 34 SIEMENS AG: COMPANY SNAPSHOT (2017) 152
FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016) 156


【レポートのキーワード】

感染症診断

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[感染症診断の世界市場予測(~2022年):製品・サービス、疾患種類、技術、エンドユーザー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆